SCHEMBL28299558

SCHEMBL28299558

FC(F)(F)CCN1CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.38
POLB P06746 2/20 0.37
LMNA P02545 2/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
CYP2D6 P10635 1/20 0.35
CHRM1 P11229 1/20 0.35
OPRM1 P35372 1/20 0.35
KCNH2 Q12809 1/20 0.35
CXCR4 P61073 2/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
PRMT8 Q9NR22 1/20 0.33
PAX8 Q06710 1/20 0.33
KCNA3 P22001 1/20 0.32
MAPT P10636 2/20 0.31
ALDH1A1 P00352 1/20 0.31
LTA4H P09960 1/20 0.31
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5311125 0.94 HRH3 (0.43) HRH3POLBLMNACHRM2HTR1A
SCHEMBL7476173 0.92 HRH3 (0.48) HRH3POLBLMNACHRM2HTR1A
SCHEMBL30135303 0.82 CXCR4 (0.44) HRH3POLBCHRM2CHRM1CXCR4
SCHEMBL1899369 0.79 POLB (0.46) POLBCHRM2CHRM1KCNH2CXCR4
SCHEMBL6889620 0.79 RAB9A (0.40) POLBCHRM2CHRM1ALDH1A1KMT2A
SCHEMBL18711629 0.78 SIGMAR1 (0.52) HRH3ALDH1A1KMT2A
SCHEMBL6484626 0.77
SCHEMBL13012623 0.77 TSHR (0.37) LMNACYP2D6ALDH1A1HTTKMT2A
Hydrochloric Acid SCHEMBL6476236 0.77 POLB (0.45) POLBCHRM2CHRM1KCNH2CXCR4
SCHEMBL1515157 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity NOVARTIS PHARMA AG (CH) 2025-12-23 US claimed
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2026-05-14 US disclosed
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity NOVARTIS PHARMA AG (CH) 2025-12-23 US disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
CN-109776523-A Heterocyclic compound and application thereof in medicine 杭州安霖药业有限公司 2019-05-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, IRF3, CGAS HRH3 1992/4885POLB 316/4885LMNA 208/4885
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity STING1, CGAS, IRF3 HRH3 1666/4885POLB 430/4885LMNA 2339/4885
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 HRH3 1666/4885POLB 430/4885LMNA 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.